Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022Article Published on 2022-11-012022-11-15 Journal: Eurosurveillance [Category] SARS, 변종, 진단, [키워드] Breakthrough infection dose evaluated HCW healthcare worker Infection infections neutralising neutralising antibody neutralising antibody titre omicron Omicron variants, neutralising antibodies SARS-CoV-2 SARS-CoV-2. uninfected vaccinated individual vaccinated individuals Vaccine variant variants wild type [DOI] 10.2807/1560-7917.ES.2022.27.44.2200785 PMC 바로가기
Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysisArticle Published on 2022-10-202022-11-15 Journal: Scientific Reports [Category] COVID19(2023년), meta-analysis, SARS, 변종, 진단, [키워드] absolute reduction article baseline Bayesian comparable Comparative COVID-19 Effect effective Effectiveness Efficacy Evidence expected generalisability healthcare high risk hospitalisation ICU admission identify individual infected individual infected with SARS-CoV-2 invasive ventilation moderate monoclonal antibody Mortality network Network meta-analysis neutralising outcome Pairwise comparison patient population patients patients treated Placebo predict Rate RCT reaction reduce mortality reducing reduction in relative risk risk reduction serious AE severe COVID-19 statistically significant reduction systematic review therapy treatment effect vaccination variant [DOI] 10.1038/s41598-022-22431-6 PMC 바로가기
A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE networkArticle Published on 2022-10-082022-11-15 Journal: Trials [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ≥75 years. adaptive addition advanced age age Analysis Antibody titre benefit BNT162b2 BNT162b2 (Comirnaty®) booster booster dose changes in Clinical course collected concern conducted COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine dose Endpoint enzyme-linked immunosorbent evaluate exploratory fourth dose humoral immune response immunosenescence include individual initial Intervention mRNA-1273 mRNA-1273 (Spikevax®) multicentre neutralising neutralising antibody titre Older Part Patient performed phase phase II primary endpoint protocol qPCR Quantitative randomisation randomised randomised controlled reactogenicity Research risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine secondary subgroup T cell response the primary endpoint Trial triggered vaccination Vaccine vaccine-induced immune response variants variants of concern VoC wild-type wild-type virus [DOI] 10.1186/s13063-022-06791-y PMC 바로가기
Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccinationArticle Published on 2022-10-012022-11-16 Journal: RMD Open [Category] COVID19(2023년), SARS, 변종, [키워드] administration Arthritis booster booster vaccination control group COVID-19 COVID-19 vaccination demonstrated Epidemiology impairment medication methotrexate mRNA MTX neutralisation neutralising Observational cohort study occur omicron Patient Prevent pseudovirus neutralisation assay reached receiving SARS-CoV-2 serum significantly higher significantly lower therapy Treatment vaccination vaccination. vaccine response variant variants were assessed while wild-type [DOI] 10.1136/rmdopen-2022-002639 PMC 바로가기
Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RAArticle Published on 2022-10-012022-11-15 Journal: RMD Open [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] Analysis anti-S IgG level anti-SARS-CoV-2 anti-SARS-CoV-2 vaccine antiviral activity assessment benefit comparable correlation COVID-19 declined demonstrated HCs healthy control identify IFN-γ ELISPOT IgA IgG IgG antibody IgG level IgG response IgM isotype IgM response IgM responses immune response mRNA neutralisation assay neutralisation assays neutralising Neutralising activity Patient performed potent predict Prophylactic Receptor binding domain regimen response Rheumatoid rheumatoid arthritis SARS-CoV-2 SARS-CoV-2 pseudovirus T cell response titre two-dose regimen vaccination. vaccine dose Viral protein [DOI] 10.1136/rmdopen-2022-002575 PMC 바로가기
Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in ArgentinaArticle Published on 2022-09-262022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] affected age aging adults Anti-spike anti-Spike IgG antibody AZD1222 B.1 BBIBP-CorV Buenos Aires Cohort Complete correlation COVID-19 COVID-19 pandemic death different time point dose elicited evaluated Evidence evidenced exhibited Gender highlighting hospitalisation humoral Humoral response IgG titer IgG titers initial management neutralising Neutralising activity Neutralising Antibodies neutralising antibodies. Older omicron pandemic participant Participants plasma sample platform provide public health resulting SARS-CoV-2 significantly higher Sputnik-V Strong vaccination vaccination schedule vaccine platform Volunteer [DOI] 10.3389/fimmu.2022.992370 PMC 바로가기
Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 VaccineArticle Published on 2022-09-132022-11-15 Journal: Viruses [Category] SARS, 변종, 진단, [키워드] B.1.1.529 BNT162b2 collected COVID-19 dose evade Immunity Improved Lineage Mutation neutralisation assay neutralise neutralising Neutralising Antibodies neutralising antibody titre omicron Pfizer-BioNTech Pfizer-BioNTech BNT162b2 raising reduced SARS-CoV-2 sera the receptor-binding domain the SARS-CoV-2 the spike protein Vaccine vaccine. variant virus VoC World Health Organization [DOI] 10.3390/v14092023 PMC 바로가기
Immune Determinants of Viral Clearance in Hospitalised COVID-19 Patients: Reduced Circulating Naïve CD4+ T Cell Counts Correspond with Delayed Viral ClearanceArticle Published on 2022-09-022022-11-15 Journal: Cells [Category] SARS, 진단, [키워드] antibody B cell basophils CD4 T cells CD4+ CD4+ T cell CD4+ T cells cellular component correlated count COVID-19 Critical cytokine profile Delayed determinant disease deterioration help hospitalised patient Humoral response IL-9 immune activation immune parameter less longitudinal design magnitude MIF moderate Monocytes naïve naïve CD4+ T cell neutralising Neutralising Antibodies Neutrophils pro-inflammatory risk stratification SARS-CoV-2 SARS-COV-2 infection severe COVID-19 severe disease T cell Th2 the timing tissue damage viral clearance Viral clearance. [DOI] 10.3390/cells11172743 PMC 바로가기
Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmissionArticle Published on 2022-09-012022-11-15 Journal: Reviews in Medical Virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] administration antibody approved Booster vaccine Combination Community consequence current Delta delta variant diagnosed dominant dominant variant Efficacy Evolution FDA higher infectivity human lung tissue immune Immune escape immune evasion Immunity immunocompromised individual IMPROVE Infection less monoclonal monoclonal antibodies Mutation mutations neutralising omicron Omicron variant Omicron. other variant Protein public health recombination event reduced reduction reported SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants several variants severity Sotrovimab spike Spread syncytia formation the SARS-CoV-2 therapeutic use Transmission Vaccine variant variants of SARS-CoV-2 Wuhan-Hu-1 zoonotic [DOI] 10.1002/rmv.2381 PMC 바로가기
Increasing anti-S antibody testing: a quality improvement initiative with evolving COVID-19 guidelinesArticle Published on 2022-09-012022-11-16 Journal: BMJ open quality [Category] 변종, [키워드] added Admission analysed anti-S anti-S antibody approach baseline Clinical practice COVID-19 COVID-19 guideline criteria eligible Final Guidance highlighting IMPROVE increase in Increasing Inpatients Intervention introduced Local management guideline monoclonal antibody Mortality neutralising observé outcomes Patient patients with COVID-19 Quality Quality improvement Quality measurement Quality measurement. reduce reduction in Research seronegative patient symptomatic variants [DOI] 10.1136/bmjoq-2022-001886 PMC 바로가기